Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06530966 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of ICP-332 in Healthy Subjects
A Phase 1 study of Healthy Subjects, sponsored by InnoCare Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06530966 is a Phase 1 study of Healthy Subjects that is actively recruiting participants, run by InnoCare Pharma. The registered enrollment target is 24 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06530966, a Phase 1 study of Healthy Subjects, is actively recruiting participants, sponsored by InnoCare Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A multiple ascending dose phase I study of ICP-332 in healthy subjects
Conditions Studied
Interventions
- DRUG ICP-332 Tablets
- DRUG ICP-332 Placebo Tablets
Study Locations (1)
Maryland
- Pharmaron CPC Inc. - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-07-23 |
| Est. Completion | 2024-12-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06530966
The ClinicalTrials.gov registry entry for NCT06530966 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (81% lower). The listed sponsor is InnoCare Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which ICP-332 Tablets is the first listed.
NCT06530966 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06530966 about?
NCT06530966 is a clinical study titled "Phase I Study of ICP-332 in Healthy Subjects". A multiple ascending dose phase I study of ICP-332 in healthy subjects
What is the current status of trial NCT06530966?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-07-23. Estimated completion is 2024-12-25.
What conditions does trial NCT06530966 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT06530966?
The interventions under investigation include: ICP-332 Tablets (DRUG), ICP-332 Placebo Tablets (DRUG).
Who is sponsoring clinical trial NCT06530966?
This trial is sponsored by InnoCare Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06530966 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
-
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.